• 1. Comparative metabolomics unveils molecular changes and metabolic networks of syringin against hepatitis B mice by untargeted mass spectrometry
  Yi-chang Jiang,Yuan-feng Li,Ling Zhou,Da-peng Zhang RSC Adv. 2020 10 461
• 2. Purification of eleutherosides by macroporous resin and the active fractions of anti-inflammatory and antioxidant activity from Acanthopanax senticosus extract
  Shun Liu,Yan Chen,Lijuan Gu,Yongxia Li,Bingyi Wang,Jie Hao,Susumu Kitanaka,Heran Li Anal. Methods 2013 5 3732
• 3. Ionic liquid–lithium salt based microwave pretreatment followed by ultrasonic-assisted extraction of syringin and oleuropein from Syringa reticulata var. mandshurica branch bark by a dual response surface methodology
  Lianfei Zhao,Hua Wang,Huiyan Gu,Lei Yang Anal. Methods 2016 8 1532
• 4. Screening of neuraminidase inhibitors from the leaves of Syringa velutina Kom. via compound fractionation and in vitro activity evaluation
  Yuchi Zhang,Jingying Xu,Chunming Liu,Sainan Li Anal. Methods 2017 9 500
• 5. Acanthopanax senticosus aqueous extract ameliorates ovariectomy-induced bone loss in middle-aged mice by inhibiting the receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis
  Huanhuan Xu,Jing Xu,Fei Chen,Titi Liu,Jin Li,Li Jiang,Yuankan Jia,Caijiang Hu,Ziqi Gao,Chunxia Gan,Lihong Hu,Xuanjun Wang,Jun Sheng Food Funct. 2020 11 9696

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Phenolic glycosides
• Pesticide Chemicals Pesticide Active Ingredients Standard Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Reference Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Syringin (CAS No: 118-34-3)

Syringin, a naturally occurring compound with the chemical formula C₁₅H₁₈O₉, is widely recognized for its significant role in the pharmaceutical and biochemical industries. Its CAS number, 118-34-3, provides a unique identifier that facilitates precise identification and classification within scientific and industrial contexts. This compound is primarily extracted from plants belonging to the Syringa genus, particularly Syringa vulgaris, and has garnered considerable attention due to its multifaceted biological activities.

The structural complexity of Syringin makes it a subject of extensive research in various fields, including medicinal chemistry and natural product research. Its molecular framework consists of a phenylpropanoid backbone, which is a hallmark of many bioactive plant-derived compounds. This structural motif contributes to its diverse pharmacological properties, making it a promising candidate for therapeutic applications.

Recent advancements in chemical biology have highlighted the potential of Syringin as an antioxidant and anti-inflammatory agent. Studies have demonstrated its ability to modulate cellular signaling pathways involved in oxidative stress and inflammation, which are key factors in numerous chronic diseases. For instance, research published in the journal *Biochemical Pharmacology* suggests that Syringin can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, thereby exhibiting significant therapeutic potential in managing inflammatory disorders.

In addition to its anti-inflammatory properties, Syringin has shown promise in cancer research. Preclinical studies indicate that it can induce apoptosis in cancer cells by activating caspase-dependent pathways. Furthermore, its ability to inhibit tyrosine kinases has led to investigations into its potential role in preventing tumor growth and metastasis. These findings have sparked interest among oncologists and pharmacologists who are exploring Syringin as a novel chemopreventive agent.

The antimicrobial properties of Syringin are another area of active investigation. Research has revealed that it can effectively inhibit the growth of various bacteria, including drug-resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA). This antimicrobial activity is attributed to its ability to disrupt bacterial cell membranes and interfere with essential metabolic processes. Such findings make Syringin a valuable candidate for developing new antimicrobial agents to combat rising antibiotic resistance.

From a pharmacokinetic perspective, the bioavailability of Syringin has been a subject of interest. Studies have shown that it can be efficiently absorbed after oral administration, although its metabolic pathways remain poorly understood. Further research is needed to elucidate how Syringin is processed within the body and to identify potential drug-drug interactions. These insights will be crucial for optimizing therapeutic dosages and ensuring safety in clinical applications.

The extraction and synthesis of Syringin present both challenges and opportunities. Traditional extraction methods often involve solvent-based processes, which can be resource-intensive and environmentally impactful. However, advancements in green chemistry have led to the development of more sustainable extraction techniques, such as supercritical fluid extraction using carbon dioxide. These methods not only improve yield but also minimize waste generation, aligning with global efforts towards sustainable pharmaceutical production.

The future of Syringin research looks promising, with ongoing studies focusing on its potential applications in neurodegenerative diseases, cardiovascular disorders, and even as a photoprotectant against UV-induced skin damage. Collaborative efforts between academia and industry are essential to translate these laboratory findings into clinical reality. As our understanding of Syringin's mechanisms of action continues to evolve, so too will its therapeutic potential.

• 183859-30-5((E)-caffeyl alcohol 4-O-beta-glucopyranoside)
• 115124-96-4(conferinoside)
• 115124-95-3(Siringinoside)
• 173357-18-1(β-D-Glucopyranose, 6-O-[(2E)-1-hydroxy-3-[4-[[6-O-[(2E)-1-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-propenyl]-β-D-glucopyranosyl]oxy]-3,5-dimethoxyphenyl]-2-propenyl]-, cyclic 1,4'''-anhydride (9CI))
• 531-29-3(Coniferin)
• 1246042-51-2(3-(4-O-alpha-D-glucopyranosyl)-3,5-dimethoxyphenyl-2E-propenol)
• 124151-33-3((E)-Coniferin)
• 109361-66-2(4-(3-hydroxyprop-1-en-1-yl)-2-methoxyphenyl beta-D-glucopyranoside)
• 139742-20-4(Me ether,4'-O-beta-glucopyranoside-Sinapyl alcohol)
• 959761-27-4(2,6-dimethoxy-4-(3-hydroxy-propen-1-yl)phenyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside)